患者及其医疗服务提供者是否在谈论长效注射抗逆转录病毒疗法？在美国三个医疗场所的临床诊疗中的普及情况。
Are Patients and Their Providers Talking About Long-Acting Injectable Antiretroviral Therapy? Penetration into Clinical Encounters at Three U.S. Care Sites.
作者信息
Christopoulos Katerina A, Colasanti Jonathan, Johnson Mallory O, Diaz Tsuzuki Manami, Erguera Xavier A, Flores Rey, Kerman Jared, Dance Kaylin, Sauceda John A, Neilands Torsten B, Dilworth Samantha E, Koester Kimberly A, Gutierrez Jose, Schneider John A, Montgomery Elizabeth, McNulty Moira C
机构信息
Division of HIV, ID and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
出版信息
Open Forum Infect Dis. 2022 Jun 11;9(7):ofac293. doi: 10.1093/ofid/ofac293. eCollection 2022 Jul.
Abstract
Use of long-acting injectable antiretroviral therapy depends on patient awareness, provider discussion, and patient willingness to use. We conducted a postvisit survey with patients at 3 HIV clinics in San Francisco, Chicago, and Atlanta in May 2021 to assess for inequities in these early implementation phases.
摘要
长效注射抗逆转录病毒疗法的使用取决于患者的认知、与医疗服务提供者的讨论以及患者使用的意愿。2021年5月，我们对旧金山、芝加哥和亚特兰大的3家艾滋病诊所的患者进行了随访后调查，以评估这些早期实施阶段中存在的不平等情况。
相似文献
1
Are Patients and Their Providers Talking About Long-Acting Injectable Antiretroviral Therapy? Penetration into Clinical Encounters at Three U.S. Care Sites.
Open Forum Infect Dis. 2022 Jun 11;9(7):ofac293. doi: 10.1093/ofid/ofac293. eCollection 2022 Jul.
2
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
BMC Health Serv Res. 2021 Mar 20;21(1):255. doi: 10.1186/s12913-021-06214-9.
3
Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial.
AIDS Res Hum Retroviruses. 2021 Mar;37(3):207-213. doi: 10.1089/AID.2020.0208. Epub 2021 Jan 19.
4
Development of a Citywide Rapid Antiretroviral Therapy Initiative in San Francisco.
Am J Prev Med. 2021 Nov;61(5 Suppl 1):S47-S54. doi: 10.1016/j.amepre.2021.06.001.
5
A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S.
AIDS Behav. 2020 Apr;24(4):1226-1236. doi: 10.1007/s10461-019-02701-7.
6
Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: A qualitative study.
Lancet Reg Health West Pac. 2022 Sep 23;31:100603. doi: 10.1016/j.lanwpc.2022.100603. eCollection 2023 Feb.
7
Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and/or housing instability.
Harm Reduct J. 2023 Jan 10;20(1):4. doi: 10.1186/s12954-023-00730-z.
8
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain.
Cult Health Sex. 2021 Aug;23(8):1066-1078. doi: 10.1080/13691058.2020.1752397. Epub 2020 May 21.
9
HIV incidence among men diagnosed with early syphilis in Atlanta, San Francisco, and Los Angeles, 2004 to 2005.
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):234-40.
10
Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention.
Infect Chemother. 2021 Dec;53(4):686-695. doi: 10.3947/ic.2021.0136.
引用本文的文献
1
Mode of administration matters: Willingness of people with HIV to switch to future long-acting treatments, and health care professionals' intention to discuss these options.
HIV Med. 2025 Sep;26(9):1395-1404. doi: 10.1111/hiv.70066. Epub 2025 Jul 2.
2
Preparing for pharmacy-based delivery of long-acting injectable antiretrovirals: a pre-implementation study.
BMC Health Serv Res. 2025 Jun 5;25(1):808. doi: 10.1186/s12913-025-12971-8.
3
Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South.
AIDS Res Hum Retroviruses. 2024 Dec;40(12):690-700. doi: 10.1089/AID.2024.0007. Epub 2024 Jul 16.
4
Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy.
AIDS Behav. 2024 Oct;28(10):3315-3325. doi: 10.1007/s10461-024-04423-x. Epub 2024 Jul 1.
5
Likelihood of Trying Long-Acting Injectable Antiretroviral Therapy Among Women With HIV in Nine Sites Across the United States.
J Acquir Immune Defic Syndr. 2024 Jul 1;96(3):e23-e27. doi: 10.1097/QAI.0000000000003422.
6
Low Uptake of Long-Acting Injectables in the First 2.5 Years Following Approval Among a Cohort of People Living With HIV.
Open Forum Infect Dis. 2024 May 16;11(5):ofae087. doi: 10.1093/ofid/ofae087. eCollection 2024 May.
7
Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.
AIDS Behav. 2024 Jul;28(7):2226-2238. doi: 10.1007/s10461-024-04315-0. Epub 2024 Apr 10.
8
"What Is the Benefit?": Perceptions and Preferences for Long-Acting Injectable Antiretroviral Therapy Among People Living With HIV.
AIDS Educ Prev. 2023 Dec;35(6):467-483. doi: 10.1521/aeap.2023.35.6.467.
9
Antiviral supramolecular polymeric hydrogels by self-assembly of tenofovir-bearing peptide amphiphiles.
Biomater Sci. 2023 Jan 17;11(2):489-498. doi: 10.1039/d2bm01649d.
本文引用的文献
1
The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?
J Int Assoc Provid AIDS Care. 2021 Jan-Dec;20:23259582211009011. doi: 10.1177/23259582211009011.
2
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
BMC Health Serv Res. 2021 Mar 20;21(1):255. doi: 10.1186/s12913-021-06214-9.
3
The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.
AIDS Res Hum Retroviruses. 2021 Feb;37(2):75-88. doi: 10.1089/AID.2020.0126. Epub 2020 Dec 7.
4
Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy.
J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):263-270. doi: 10.1097/QAI.0000000000002337.
5
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain.
Cult Health Sex. 2021 Aug;23(8):1066-1078. doi: 10.1080/13691058.2020.1752397. Epub 2020 May 21.
6
Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection.
AIDS Care. 2021 Jun;33(6):801-809. doi: 10.1080/09540121.2020.1764906. Epub 2020 May 14.
7
Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis - United States, 2013-2018.
MMWR Morb Mortal Wkly Rep. 2019 Dec 6;68(48):1117-1123. doi: 10.15585/mmwr.mm6848e1.
8
Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV.
AIDS Patient Care STDS. 2019 Mar;33(3):104-111. doi: 10.1089/apc.2018.0198.
9
Interest of Youth Living With HIV in Long-Acting Antiretrovirals.
J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):190-197. doi: 10.1097/QAI.0000000000001896.
10
HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016.
MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1147-1150. doi: 10.15585/mmwr.mm6741a3.
Zotero 插件